Yeji

$NUVB

Nuvation Bio Inc.

Runway:cash-flow +
NYSEMarket cap: —CIK 0001811063

Upcoming catalysts

2 surfaced
FDA approvalDate TBD
$NUVBNuvation Bio Inc.
ibtrozi
“Approved by the U.S. FDA in June 2025”
NDA/BLA filedDate TBD
$NUVBNuvation Bio Inc.
taletrectinib · advanced ROS1-positive non-small cell lung cancer (NSCLC)
“U.S. Food and Drug Administration\'s acceptance and priority review of the Company\'s New Drug Application for taletrectinib for the treatment of advanced ROS1-positive NSCLC”

Drug pipeline

ibtrozi
taletrectinib
advanced ROS1-positive non-small cell lung cancer (NSCLC)
safusidenib
Glioma
NUV-868
Advanced Solid Tumor
Multiple administration of omeprazole Single administration of AB-106
Pharmacokinetic Study
DS6051b
Solid Tumors
AB-106
Solid Tumor
NUV-422
Prostate Cancer
AB-106, Itraconazole
Solid Tumor
NUV-1511
Advanced Solid Tumor
AB-106, digoxin
Solid Tumor

Recent & active trials

NCTDrugPhaseStatusPrimary completion
NCT07154706taletrectinibPhase 3Recruiting2030-08-30
NCT06564324taletrectinibPhase 3Recruiting2029-01-01
NCT05303519safusidenibPhase 3Recruiting2028-12-01
NCT06334432NUV-1511Phase 2Active Not Recruiting2027-03-01
NCT04919811taletrectinibPhase 2Active Not Recruiting2025-06-11
NCT05191004NUV-422Phase 2Withdrawn2025-06-01
NCT05191017NUV-422Phase 2Withdrawn2025-01-01
NCT04617054AB-106Phase 2Terminated2024-12-06
NCT05252390NUV-868Phase 1Terminated2024-07-15
NCT04395677AB-106Phase 2Active Not Recruiting2024-06-07
NCT05609929Multiple administration of omeprazole Single administration of AB-106Phase 1Completed2023-01-20
NCT04541225NUV-422Phase 1Terminated2022-08-31
NCT05357820AB-106, ItraconazolePhase 1Completed2021-12-03
NCT05357911AB-106, digoxinPhase 1Completed2021-08-20
NCT02279433DS6051bPhase 1Completed2019-03-01
NCT06841874taletrectinib—No Longer Available—

Recent catalysts

FDA approvalJun 11, 2025· 360d ago· success
$NUVBNuvation Bio Inc.
ibtrozi
“openFDA ORIG (TYPE 1) approval of IBTROZI — application NDA219713”